Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes.

"Declarations Conflict of interestC.S. received research funding from Böhringer Ingelheim, Ingelheim, Germany. All other authors declare that they have no competing interests. Ethical approvalThe study protocol involving human tissue samples was approved by the responsible Ethics Committee of the Medical Faculty of Heidelberg University (Germany; S-017/2013) and was conducted in accordance with the 1964 Declaration of Helsinki. Human induced pluripotent stem cell (hiPSC) line UMGi014-C clone 14 (isWT1.14) was derived from dermal fibroblasts of a healthy male donor and experimental protocols were approved by the ethics committee of the University Medical Center Göttingen (10/9/15). All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals adopted by the US National Institutes of Health (NIH publication No. 86–23, revised 1985), with EU Directive 2010/63/EU, with the current version of the German Law on the Protection of Animals, and the ARRIVE guidelines. The study protocol was approved by the local Animal Welfare Committee (Regierungspräsidium Karlsruhe, Germany, reference numbers G-165/19; G-67/20; G-229/21). Informed consentWritten informed consent was obtained from all individual participants included in the study. Conflict of interest C.S. received research funding from Böhringer Ingelheim, Ingelheim, Germany. All other authors declare that they have no competing interests."

"Funding Open Access funding enabled and organized by Projekt DEAL."